Morgan Stanley says shares of Cardinal Health should rally on the company’s “solid” fiscal Q3 pharma growth and higher 2025 targets. There was investor scrutiny heading into the print and focus should turn to Cardinal’s slightly better preliminary fiscal 2025 guidance, the analyst tells investors in a research note. The firm raised fiscal 2024 and 2025 earnings estimates and keeps an Overweight rating on the shares with a $114 price target. The stock in afternoon trading is up 53c to $102.65.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health Executives Discuss Quarterly Results and Future Projections
- Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance
- Cardinal Health Stock (NYSE:CAH): Dip Creates Long-Term Opportunity
- CAH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cardinal Health price target lowered to $94 from $96 at Wells Fargo